Handa

Crohn's disease is a chronic inflammatory condition affecting the digestive tract that currently has no cure. This research aims to evaluate the safety and effectiveness of upadacitinib in treating moderate to severe active Crohn's disease in a real-world setting in Japan. The study will monitor any adverse events and changes in disease activity among participants. All participants will receive upadacitinib as prescribed by their doctors following local approved guidelines. Around 240 participants will be enrolled, and treatment will be according to each participant's usual clinical care. The study is observational and non-interventional, meaning no additional treatments or procedures beyond standard care will be required. Participants will be followed for up to 64 weeks, with study visits conducted either in person or virtually according to standard care practices. Researchers will assess safety by tracking serious infections related to the drug and monitor disease activity throughout the study period. There is expected to be no extra burden on participants beyond their routine care and assessments.

Researchers are investigating the effects of starting finerenone treatment early during hospitalization for patients with acute heart failure who have a left ventricular ejection fraction of 40% or higher. This Phase 4, multicenter, randomized, double-blind, placebo-controlled trial aims to assess whether early use of finerenone can improve outcomes in this patient group. Participants are randomly assigned to receive either finerenone or a matching placebo tablet. The finerenone dosing depends on kidney function: patients with an estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73 m² or less start at 10 mg once daily, with a maximum dose of 20 mg once daily; those with eGFR above 60 mL/min/1.73 m² start at 20 mg once daily, with a maximum dose of 40 mg once daily. Treatment begins within 36 hours after hospital admission, with randomization occurring within 24 hours. During the study, participants will be monitored for up to 12 weeks to evaluate a combined outcome of death and worsening heart failure. Researchers will conduct assessments including physical exams, symptom evaluation, laboratory tests, and heart function measurements. Safety and adherence to treatment will be tracked throughout the study, ensuring comprehensive evaluation of the therapy's impact during the critical early phase of hospitalization.

This research observes patients with Paroxysmal Nocturnal Hemoglobinuria who are treated with Fabhalta capsules. It is a multicenter, single-arm, non-interventional study designed to monitor drug use and safety over time. The study uses a central registration and all-case surveillance system to collect data. Participants will be observed for 48 weeks after starting Fabhalta treatment. If treatment stops within this period, any adverse events and use of other medications will be tracked up to 30 days after the last treatment day. There are no additional interventions or comparison groups in this study. During the study, researchers will monitor the occurrence of infections and other adverse events through case report forms. Participants' health and drug usage will be recorded throughout the observation period. The total participation lasts for 48 weeks, focusing on safety and drug use in real-world settings.